Comparison of Six Cycles with Four Cycles of Chemotherapy and Atezolizumab in the First-Line Treatment of ES-SCLC; A Retrospective Multicenter Analysis

Extending the Carboplatin, Etoposide and Atezolizumab induction to six-cycles did not improve either PFS or OS comparing to standard four-cycle regimen. However, it may be considered in patients who do not have baseline brain metastasis, since the intracranial progression rate is significantly lower in the six-cycle group of our study and this effect of prolonged treatment was observed predominantly in patients without baseline brain metastasis. The immune-related adverse events were similar across the six-cycle and the four-cycle groups.

Authors

Institutions

Publication Details

Journal
The Oncologist
Published
2026-03-12
DOI
https://doi.org/10.1093/oncolo/oyag092
Primary Topic
Lung Cancer Research Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Comparison of Six Cycles with Four Cycles of Chemotherapy and Atezolizumab in the First-Line Treatment of ES-SCLC; A Retrospective Multicenter Analysis

M. Erman, Kadir Eser, Safa Can Efil, Tuba Karaçelik et al.
The Oncologist
Lung Cancer Research Studies
article

Comparison of Six Cycles with Four Cycles of Chemotherapy and Atezolizumab in the First-Line Treatment of ES-SCLC; A Retrospective Multicenter Analysis

M. Erman, Kadir Eser, Safa Can Efil, Tuba Karaçelik, TUĞBA BAŞOĞLU TÜYLÜ, Seval Orman, Serdar Karakaya, Onur Baş, Halil Çelik, Esra Zeynelgil, Aytac Terzi, Yasemi̇n Kemal, Çağlar Köseoğlu, Cengiz Akosman, Banu Öztürk, Alper Coşkun, Elif Atağ, D. Kivrak Salim, N. Karadurmus, BURAK BİLGİN, Saadettin Kılıçkap, Melek Karakurt Eryılmaz, Halil Göksel Güzel, Erdem Çubukçu
article en

Abstract

Extending the Carboplatin, Etoposide and Atezolizumab induction to six-cycles did not improve either PFS or OS comparing to standard four-cycle regimen. However, it may be considered in patients who do not have baseline brain metastasis, since the intracranial progression rate is significantly lower in the six-cycle group of our study and this effect of prolonged treatment was observed predominantly in patients without baseline brain metastasis. The immune-related adverse events were similar across the six-cycle and the four-cycle groups.

The Oncologist
Bursa Uludağ Üni̇versi̇tesi̇ (TR), Bilkent University (TR), Dokuz Eylül University (TR), Gülhane Askerî Tıp Akademisi (TR), Ankara Atatürk Eğitim ve Araştırma Hastanesi (TR), Memorial Ankara Hospital (TR), Dr Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesi (TR), Necmettin Erbakan University (TR), Antalya Eğitim ve Araştırma Hastanesi (TR), Hacettepe University Hospital (TR), Samsun University (TR), Başkent University Hospital (TR), Liv Hospital (TR), Mersin Üniversitesi (TR), Ordu University (TR)
Good health and well-being
Openalex Percentile: Top 21%
Lung Cancer Research Studies
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.